Lynn Seely's most recent trade in Lyell Immunopharma Inc was a trade of 412 Common Stock done at an average price of $16.1 . Disclosure was reported to the exchange on Nov. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.11 per share. | 10 Nov 2025 | 412 | 67,159 | - | 16.1 | 6,637 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 175,000 | 175,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2025 | 40,000 | 74,828 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.54 per share. | 20 Aug 2025 | 7,257 | 67,571 | - | 10.5 | 76,518 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 11 Aug 2025 | 406 | 34,828 | - | 10.3 | 4,197 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 11 Aug 2025 | 391 | 35,234 | - | 10.5 | 4,116 | Common Stock |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 128.12 per share. | 18 Jun 2025 | 3,902 | 17,156 (0%) | 0% | 128.1 | 499,924 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 14 Mar 2025 | 175,000 | 712,500 | - | 0.6 | 106,190 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,350,000 | 1,350,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 337,500 | 537,500 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 168,750 | 168,750 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 13,254 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 200,000 | 200,000 | - | 0 | Common Stock | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 11,012 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 7,500,000 | 7,500,000 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 2,600 | 8,412 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock |